Meloxicam

Meloxicam Reactions 1704, p235 - 2 Jun 2018 Toxic epidermal necrolysis: case report A 32-year-old man developed toxic epidermal necrolysis (TEN) during treatment with meloxicam for lower back pain [route and frequency not stated]. The man, who had lower back pain, started receiving meloxicam 15mg. Within hours of meloxicam administration, he developed a diffuse erythematous urticaria-like eruptions on the chest and on the trunk. Two days later, the man was treated with prednisolone. However, over the next three days, he developed blisters of the lateral tongue, oral mucosa, lips and scrotum. A dermatological review detected target-like lesions and a positive Nikolsky’s sign on the genitals, along with the urticaria-like eruptions. He was then admitted to a hospital for biopsies of his upper torso. The active blistering sites of the genital region clinically suggested SJS; however, the result of the pathological examination confirmed the diagnosis of TEN. He received treatment with IV immunoglobulin and ciclosporin for three days, to which he responded well. Author comment: "COX-2 inhibitors are well-documented as being high risk medications for Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrosis (TEN). However, there is little evidence associating meloxicam specifically with these conditions." "A pathological diagnosis of TEN was made with the provision that the active blistering sites of the genital region clinically suggest SJS." Ellsmore J, et al. A case of meloxicam induced early toxic epidermal necrosis in a 32-year-old caucasian male. Australasian Journal of Dermatology 59 (Suppl. 1): 87 (plus poster), 27 Apr 2018. Available from: URL: https://doi.org/10.1111/ ajd.17_12815 [abstract] - Australia 803323581 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Meloxicam

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/meloxicam-rsiH9xxOzb
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46878-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p235 - 2 Jun 2018 Toxic epidermal necrolysis: case report A 32-year-old man developed toxic epidermal necrolysis (TEN) during treatment with meloxicam for lower back pain [route and frequency not stated]. The man, who had lower back pain, started receiving meloxicam 15mg. Within hours of meloxicam administration, he developed a diffuse erythematous urticaria-like eruptions on the chest and on the trunk. Two days later, the man was treated with prednisolone. However, over the next three days, he developed blisters of the lateral tongue, oral mucosa, lips and scrotum. A dermatological review detected target-like lesions and a positive Nikolsky’s sign on the genitals, along with the urticaria-like eruptions. He was then admitted to a hospital for biopsies of his upper torso. The active blistering sites of the genital region clinically suggested SJS; however, the result of the pathological examination confirmed the diagnosis of TEN. He received treatment with IV immunoglobulin and ciclosporin for three days, to which he responded well. Author comment: "COX-2 inhibitors are well-documented as being high risk medications for Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrosis (TEN). However, there is little evidence associating meloxicam specifically with these conditions." "A pathological diagnosis of TEN was made with the provision that the active blistering sites of the genital region clinically suggest SJS." Ellsmore J, et al. A case of meloxicam induced early toxic epidermal necrosis in a 32-year-old caucasian male. Australasian Journal of Dermatology 59 (Suppl. 1): 87 (plus poster), 27 Apr 2018. Available from: URL: https://doi.org/10.1111/ ajd.17_12815 [abstract] - Australia 803323581 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off